natgillin/translations-raw huggingface dataset:
Levetiracetam has been given to you by your doctor to reduce the number of fits.
Levetiracetam Vam je propisao Vaš liječnik kako bi se smanjio broj napadaja.
• If you notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor.
• Ako primijetite usporen rast ili neočekivan razvoj djeteta u pubertetu, obavijestite svog liječnika.
Contents of the pack and other information What Levetiracetam Actavis contains
Sadržaj pakiranja i druge informacije Što Levetiracetam Actavis sadrži
The active substance is called levetiracetam.
Djelatna tvar se zove levetiracetam.
Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Razine metotreksata i levetiracetama treba pažljivo nadzirati kod bolesnika koji se istovremeno liječe s ova dva lijeka.
Ks= 0.45 in Term infants to 1 year old; ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male.
ks = 0,45 za dojenčad do 1. godine života rođene u terminu; ks = 0,55 za djecu mlađu od 13 godina i za adolescente ženskog spola; ks = 0,7 za adolescente muškog spola.
The daily dose is administered in two equally divided doses.
Dnevna doza primjenjuje se podijeljena u dvije jednake doze.
The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults.
Prividni tjelesni klirens korigiran za tjelesnu težinu bio je približno 30% veći nego u odraslih s epilepsijom.
Should your doctor decide to stop your Levetiracetam Actavis treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Actavis.
Ako Vaš liječnik odluči prekinuti Vaše liječenje Levetiracetamom Actavis, on/ona uputit će Vas da postupno prekinete uzimanje Levetiracetama Actavis.
When you will first start taking Levetiracetam Actavis, your doctor will prescribe you a lower dose (500 mg each day) during 2 weeks before giving you the lowest general dose of 1,000 mg.
Kad prvi put počnete uzimati Levetiracetam Actavis, liječnik će Vam propisati manju dozu (500 mg svaki dan) tijekom 2 tjedna prije davanja najmanje uobičajene doze od 1000 mg.
Levetiracetam has minor or moderate influence on the ability to drive and use machines.
Levetiracetam ima manji ili umjereni utjecaj na sposobnost upravljanja vozilima i rada sa strojevima.
Talk to your doctor before taking Levetiracetam Actavis
Obratite se svom liječniku prije nego uzmete Levetiracetam Actavis
Mogilska 80, 31-546 Kraków, Poland
Mogilska 80. 31-546 Krakow, Poljska
Do not use this medicine after the expiry date which is stated on the carton, label or blister after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji, naljepnici ili blisteru iza oznake „EXP“.
The major route of excretion was via urine, accounting for a mean 95 % of the dose (approximately 93 % of the dose was excreted within 48 hours).
Levetiracetam se uglavnom izlučuje putem urina, i to 95% doze (približno 93% doze izluči se za 48 sati).
In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study.
Pored toga, 101 dojenče mlađe od 12 mjeseci bilo je izloženo lijeku u postmarketinškim ispitivanjima
30 tablets 100 tablets 200 tablets
30 tableta 100 tableta 200 tableta
The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.
Kumulativno izlučivanje levetiracetama i njegovog glavnog metabolita urinom iznosi 66% odnosno 24% doze tijekom prvih 48 sati.
What Levetiracetam Actavis looks like and contents of the pack
Kako Levetiracetam Actavis izgleda i sadržaj pakiranja
Epilepsy is a condition where the patients have repeated fits (seizures).
Epilepsija je stanje kod kojeg bolesnik ima ponovljene napadaje.
How to store Levetiracetam Actavis Contents of the pack and other information
Kako čuvati Levetiracetam Actavis Sadržaj pakiranja i druge informacije
Add-on therapy for infants aged from 1 month to less than 6 months
Dodatna terapija za dojenčad u dobi od 1 mjeseca do manje od 6 mjeseci
Therefore, the interaction of Levetiracetam Actavis with other substances, or vice versa, is unlikely.
Iz toga proizlazi da interakcija lijeka Levetiracetam Actavis s drugim tvarima, i obrnuto, nije vjerojatna.
If you take more Levetiracetam Actavis than you should
Ako uzmete više lijeka Levetiracetam Actavis nego što ste trebali
It is therefore recommended to adjust the maintenance daily dose of Levetiracetam Actavis, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).
Stoga se preporučuje prilagođavanje dnevne doze održavanja lijeka Levetiracetam Actavis s obzirom na klirens kreatinina u bolesnika s umjerenim i teškim oštećenjem bubrega (vidjeti dio 4.2).
The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.
Djelatna tvar, levetiracetam, jest derivat pirolidona (S-enantiomer α-etil-2-okso-1-pirolidin acetamida), kemijski različit od postojećih antiepileptičnih djelatnih tvari.
In all of the above cases an oral solution should be used.
U svim tim slučajevima treba upotrijebiti oralnu otopinu.
The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, using the following formula:
Klirens kreatinina u ml/min može se procijeniti iz serumskog kreatinina (mg/dl), za odrasle i adolescente teške 50 kg ili više, pomoću sljedeće formule:
No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy.
Nisu identificirane nove sigurnosne bojazni za dojenčad mlađu od 12 mjeseci koja boluje od epilepsije.
• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome);
• rasprostranjeni osip s mjehurićima i kožom koja se ljušti, posebice oko usta, nosa, očiju i genitalija (Stevens-Johnsonov sindrom)
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to
Nuspojave su prikazane prema opadajućoj ozbiljnosti i njihova je učestalost definirana na sljedeći način: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često
35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months.
Trideset i pet dojenčadi mlađe od godine dana s parcijalnim napadajima bili su izloženi lijeku u placebom kontroliranim kliničkim ispitivanjima od kojih su samo njih 13 bili mlađi od 6 mjeseci.
In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg.
Ujedno, dostupne doze tableta nisu prikladne za početak liječenja u djece lakše od 25 kg, u bolesnika koji ne mogu gutati tablete ili za davanje doza manjih od 250 mg.
* The colourants are:
*Bojila su:
Other medicines and Levetiracetam Actavis
Drugi lijekovi i Levetiracetam Actavis
Therefore, there is no need for plasma level monitoring of levetiracetam.
Stoga nije potrebno praćenje razine levetiracetama u plazmi.
Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels.
Zabilježeno je da istovremena primjena levetiracetama i metotreksata smanjuje kliren metotreksata što rezultira u povećanoj/produljenoj koncentraciji metotreksata u krvi do potencijalno toksičnih razina.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton for Aluminium/PVC blisters
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija za aluminij/PVC blistere
In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50 % due to a concomitant renal impairment (see section 4.2).
U većine osoba s teškim oštećenjem jetre klirens levetiracetama smanjen je za više od 50% uslijed popratnog oštećenja bubrega (vidjeti dio 4.2).
250 mg tablet: Indigo carmine (E132).
250 mg tableta: indigo carmine (E132).
The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam.
Profil nuspojave opisan niže temelji se na analizi zbirnih placebom konroliranih kliničkih istraživanja za sve ispitivane indikacije, u kojima je levetiracetamom liječeno ukupno 3416 bolesnika.
Perforated unit dose blisters: 60 x 1 film-coated tablets (only available for 250 mg, 500 mg and 1,000 mg tablets).
Perforirani blisteri djeljivi na jedinične doze: 60 x 1 filmom obloženih tableta (dostupni samo za tablete od 250 mg, 500 mg i 1000 mg).
An oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescents (from 6 to 17 years) weighing less than 50 kg and when tablets do not allow accurate dosage.
Oralna otopina je prikladnija formulacija za primjenu u dojenčadi i djece mlađe od 6 godina i za djecu i adolescente (od 6 do 17 godina) koja teže manje od 50 kg i kada tablete ne dozvoljavaju točno doziranje.
The dose level of 1,800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of foetuses with cardiovascular/skeletal anomalies.
Doza od 1800 mg/kg/dan izazvala je znatnu maternalnu toksičnost i smanjenje fetalne težine, povezane s povećanom pojavnošću fetusa s anomalijama srčano-žilnog sustava i kostura.
Actavis treatment for as long as your doctor has told you.
Levetiracetam Actavis onoliko dugo koliko je liječnik odredio.
• Levetiracetam Actavis is used as a chronic treatment.
• Levetiracetam Actavis se koristi za dugotrajno liječenje.
Adverse reactions reported in clinical studies (adults, adolescents, children and infants >1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency.
Nuspojave zabilježene tijekom kliničkih ispitivanja (odrasli, adolescenti, djeca i dojenčad starija od 1 mjeseca) ili iskustva nakon stavljanja lijeka u promet navedene su u sljedećoj tablici s obzirom na organski sustav i učestalost.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type
Studije in vitro pokazuju da levetiracetam utječe na razinu Ca2+ u neuronima na način da djelomično inhibira
Perforated unit dose blisters: 60 x 1 film-coated tablets.
Perforirani blisteri djeljivi na jedinične doze: 60 x 1 filmom obloženih tableta.
However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline.
No u ispitanika koji su uzimali levetiracetam tijekom dugoročnog, otvorenog ispitivanja provedenog praćenjem u prosjeku nije bilo pogoršanja bihevioralnog i emocionalnog funkcioniranja, a osobito nije bilo pogoršanja pokazatelja agresivnog ponašanja u odnosu na početno stanje.
The adverse reaction profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications.
Profil nuspojave levetiracetama općenito je sličan u svim starosnim skupinama i u svim odobrenim indikacijama epilepsije.
• skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (StevensJohnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis).
• osip kože koji se može formirati u mjehuriće i izgledati kao male mete (sa središnjim tamnim točkama okruženim bljeđim područjem i tamnim prstenom oko ruba) (erythema multiforme), jako rasprostranjen osip s mjehurićima i kožom koja se ljušti, osobito oko usta, nosa, očiju i genitalija (Stevens-Johnsonov sindrom), i mnogo teži oblik koji uzrokuje ljuštenje kože na više od 30% površine tijela (toksična epidermalna nekroliza).
58.3 % of the levetiracetam treated patients and 23.3 % of the patients on placebo had at least a 50 % reduction in myoclonic seizure days per week.
58,3% bolesnika liječenih levetiracetamom i 23,3% bolesnika koji su dobivali placebo imalo je barem 50%-tno smanjenje broja dana s miokloničkim napadajima tjedno.
500 to 1,500 mg twice daily 500 to 1,000 mg twice daily 250 to 750 mg twice daily
500 do 1500 mg dva puta na dan 500 do 1000 mg dva puta na dan 250 do 750 mg dva puta na dan
In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 AND UGT1A6]) and epoxide hydroxylase activities.
In vitro je pokazano da levetiracetam i njegov glavni metabolit ne inhibiraju aktivnost izoformi glavnog humanog citokroma P450 (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 i 1A2), glukuronil transferaze
If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/kg twice daily every two weeks).
(primjerice, kod odraslih i adolescenata koji su teži više od 50 kg: smanjenja doze od 500 mg dva puta na dan svaka dva do četiri tjedna; u dojenčadi starije od 6 mjeseci, djece i adolescenata koji teže manje od 50 kg: smanjenje doze ne smije premašiti 10 mg/kg dva puta na dan svaka dva tjedna; u dojenčadi (mlađe od 6 mjeseci): smanjenje doze ne smije premašiti 7 mg/kg dva puta na dan svaka dva tjedna).
Tjoapack Netherlands B.V. Nieuwe Donk 9, ETTEN-LEUR, 4879AC, Netherlands
Nieuwe Donk 9, ETTEN-LEUR, 4879AC, Nizozemska
In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1,000, 2,000 or 3,000 mg levetiracetam respectively and of 12.6 % for patients on placebo.
Analizom zbirnih podataka utvrđeno je da je postotak bolesnika kod kojih je postignuto 50%-tno ili više smanjenje od početne učestalosti djelomičnih napadaja tjedno uz konstantnu dozu (12/14 tjedana) bio 27,7% kod uzetih 1000 mg, 31,6% kod uzetih 2000 mg i 41,3% kod uzetih 3000 mg levetiracetama te 12,6% kod uzimanja placeba.
Each film-coated tablet contains 0.156 mg sunset yellow E110.
Jedna filmom obložena tableta sadrži 0,156 mg boje sunset yellow E110.
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common.
Na početku liječenja ili povećanja doze nuspojave, nuspojave poput pospanosti, umora i omaglice, mogu se češće javiti.
Levetiracetam Actavis 750 mg contains colouring agent sunset yellow (E110) which may cause allergic reactions.
Levetiracetam Actavis 750 mg sadrži boju sunset yellow (E110) koja može uzrokovati alergijske reakcije.
Add-on therapy for adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more The initial therapeutic dose is 500 mg twice daily.
Dodatna terapija za odrasle (≥18 godina) i adolescente (12 do 17 godina) teške 50 kg ili više Početna terapijska doza iznosi 500 mg dva puta na dan.
Sunset Yellow (E110) colouring agent may cause allergic reactions.
Bojilo sunset yellow FCF (E110) može izazvati alergijske reakcije.
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents, children and infants, using the following formula (Schwartz formula):
Klirens kreatinina u ml/min/1,73 m2 može se za mlade adolescente, djecu i dojenčad procijeniti iz vrijednosti serumskoga kreatinina (mg/dl) s pomoću sljedeće formule (Schwartzova formula):
What you need to know before you take Levetiracetam Actavis Do not take Levetiracetam Actavis
Što morate znati prije nego počnete uzimati Levetiracetam Actavis
The mechanism of action of levetiracetam still remains to be fully elucidated.
Mehanizam djelovanja Mehanizam djelovanja levetiracetama nije u potpunosti razriješen.
Peak concentrations (Cmax) are typically 31 and 43 μg/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively.
Vršna koncentracija (Cmax) uglavnom je 31 μg/ml nakon jedne doze od 1000 mg i 43 μg/ml nakon ponovljene doze od 1000 mg dva puta na dan.
CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73 BSA subject (m2)
CLcr (ml/min/1,73 m2) = ---------------------------- x 1,73 PT bolesnika (m2)
For children 6 years and above, an oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
Za djecu od 6 godina i stariju, oralnu otopinu treba koristiti za doze ispod 250 mg, za doze koje nisu višestruke doze od 250 mg kada se preporuka za doziranje ne može postići uzimanjem više tableta i za bolesnike koji ne mogu gutati tablete.
You should not drive or use machines until it is established that your ability to perform such activities is not affected.
Ne smijete voziti ili se koristiti strojevima dok se ne utvrdi da uzimanje lijeka Levetiracetam Actavis ne utječe na Vaše sposobnosti za to.
Specifar S.A 1, 28 Octovriou str. 123 51 Ag. Varvara Athens
1, 28 Octovriou str., 123 51 Ag.
The fractional removal of levetiracetam was 51 % during a typical 4-hour dialysis session.
Frakcijsko uklanjanje levetiracetama iznosi 51% tijekom uobičajene četverosatne dijalize.
More than half of the subjects remained seizure free for 12 months (56.6 % and 58.5 % of subjects on levetiracetam and on carbamazepine CR respectively).
Više od pola ispitanika 12 mjeseci nije imalo napadaje (56,6% bolesnika koji su dobivali levetiracetam i 58,5% ispitanika koji su dobivali karbamazepin s kontroliranim otpuštanjem).
Levetiracetam Actavis is not indicated in children and adolescents below 16 years on its own (monotherapy).
Levetiracetam Actavis nije indiciran u djece i adolescenata mlađih od 16 godina kao monoterapija.
Tablet containers: 30, 100 and 200 film-coated tablets.
Spremnici s tabletama: 30, 100 i 200 filmom obloženih tableta.
The risk of anorexia is higher when levetiracetam is coadministered with topiramate.
Opis izdvojenih nuspojava Rizik anoreksije veći je ako se levetiracetam uzima istodobno s topiramatom.
Creatinine clearance (ml/min/1.73 m2)
Klirens kreatinina (ml/min/1,73 m2)
• primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
primarno generaliziranih toničko-kloničkih napadaja (velikih napadaja, uključujući gubitak svijesti) u odraslih i adolescenata starijih od 12 godina života s idiopatskom generaliziranom epilepsijom (vrsta epilepsije za koju se misli da je genetski uzrokovana).
Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function
Prilagođavanje doze za odrasle bolesnike i adolescente teške više od 50 kg s oštećenom bubrežnom funkcijom
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy.
Djelotvornost levetiracetama za samostalno liječenje dokazana je kod paralelnih grupa u dvostruko slijepoj usporedbi neinferiornosti s karbamazepinom s kontroliranim otpuštanjem (CR, engl. controlled release) na 576 bolesnika u dobi od 16 godina ili starijih s novo- ili nedavno dijagnosticiranom epilepsijom.
Drug reaction with eosinophilia and systemic symptoms (DRESS), hypersensitivity (including angioedema and anaphylaxis)
Reakcija na lijek s eozinofilijom i sistemskim simptomima (DRESS), preosjetljivost
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1,000 mg film-coated tablets
Levetiracetam Actavis 250 mg filmom obložene tablete Levetiracetam Actavis 500 mg filmom obložene tablete Levetiracetam Actavis 750 mg filmom obložene tablete Levetiracetam Actavis 1000 mg filmom obložene tablete levetiracetam
An oral solution is the preferred formulation for use in infants and children under the age of 6 years.
Oralna otopina je poželjna formulcija za primjenu u dojenčadi i djece mlađe od 6 godina.
White tablet containers (HDPE) closed with snap-on cap (LDPE) with a tamper evident ring.
Bijeli spremnici (HDPE) s tabletama zatvoreni zatvaračem (LDPE) i zaštitnim prstenom s evidencijom otvaranja.
• myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
miokloničkih napadaja (kratkih, šoku nalik trzanja mišića ili skupine mišića) u odraslih i adolescenata starijih od 12 godina života s juvenilnom miokloničnom epilepsijom;
A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six month and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 month to less than 4 years old, was used in this study.
20 mg/kg/dan titrirana je do 40 mg/kg/dan u dojenčadi u dobi od jednog do manje od 6 mjeseci, a doza od 25 mg/kg/dan titrirana je do 50 mg/kg/dan u dojenčadi i djece u dobi od 6 mjeseci do manje od 4
The tablet formulation is not adapted for use in infants and children under the age of 6 years.
Farmaceutski oblik tableta nije prilagođena za primjenu u dojenčadi i djece mlađe od 6 godina.
Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more:
Doza u odraslih i adolescenata (12 do 17 godina) koji imaju 50 kg ili više:
The possible side effects of an overdose of levetiracetam are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Moguće nuspojave predoziranja levetiracetamom su pospanost, uznemirenost, agresija, smanjena pozornost, smetnje disanja i koma.
If you stop taking Levetiracetam Actavis
Ako prestanete uzimati Levetiracetam Actavis
72.2 % of the levetiracetam treated patients and 45.2 % of the patients on placebo had a 50 % or greater decrease in the frequency of PGTC seizures per week.
U 72,2% bolesnika liječenih levetiracetamom i 45,2% bolesnika koji su dobivali placebo primijećeno je 50%-tno ili više smanjenje učestalosti PGTK napadaja tjedno.
43.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo were considered as responders.
U 44,6% bolesnika liječenih levetiracetamom i 19,6% bolesnika koji su dobivali placebo, zapaženo je
If stopping treatment, Levetiracetam Actavis should be discontinued gradually to avoid an increase of seizures.
Ako prekidate liječenje lijekom Levetiracetam Actavis prekid mora biti postupan kako bi se izbjeglo pojačanje napadaja.
Renal impairment The daily dose must be individualised according to renal function.
Dnevna doza određuje se za svakog bolesnika pojedinačno u skladu s bubrežnom funkcijom.
If you forget to take Levetiracetam Actavis
Ako ste zaboravili uzeti Levetiracetam Actavis
Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2 %
73,0% bolesnika liječenih levetiracetamom i 72,8% bolesnika liječenih karbamazepinom s kontroliranim otpuštanjem (CR) bilo je šest mjeseci bez napadaja: prilagođena apsolutna razlika između liječenja bila je 0,2% (95% CI: -7,8 8,2).